Literature DB >> 25642939

Access sought to tuberculosis drug from nutraceutical company.

Karl Gruber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25642939     DOI： 10.1038/nm.3805

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

1.  Timing is everything for compassionate use of delamanid.

Authors:  Clifton E Barry
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

Review 2.  Drug-Resistant Tuberculosis: Challenges and Progress.

Authors:  Sebastian G Kurz; Jennifer J Furin; Charles M Bark
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

Review 3.  The role of delamanid in the treatment of drug-resistant tuberculosis.

Authors:  Joseph M Lewis; Derek J Sloan
Journal:  Ther Clin Risk Manag       Date:  2015-05-13       Impact factor: 2.423

Review 4.  Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.

Authors:  Derek J Sloan; Joseph M Lewis
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.